ArticleQuantitative imaging in medicine and surgery2025
Evolution of transarterial chemoembolization-related liver abscess over time: a systematic review and meta-analysis.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transarterial chemoembolization with prophylactic right inferior phrenic artery embolization for hepatocellular carcinoma in segments VII and VIII.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is a primary method for treating malignant liver tumors; however, the occurrence of liver abscesses after TACE has always been a concern. With the evolution of time, TACE techniques and practical experience continue to advance, leading to a deeper understanding of post-TACE liver abscesses. This meta-analysis aimed to comprehensively examine the occurrence of liver abscesses after TACE and focus on its changing trends. Methods: Two researchers reviewed the databases of PubMed, Embase, and Web of Science to identify articles that reported liver abscess formation after TACE in patients with hepatic malignant tumor. The search was conducted from the date of establishment of each database up to January 2023. After screening the articles and extracting the data, we used Review Manager 5.3 and Stata 16.0 for analysis and processing. Results: This meta-analysis included a total of 32 studies, comprising 254,408 TACE patients, of whom 642 developed liver abscesses after TACE. The pooled incidence rate of liver abscess formation after TACE was 0.54%. The heterogeneity was considerable and significant. Subgroup analysis revealed a significant impact of the evolution of time on the incidence of liver abscess formation after TACE. The incidence was shown to have decreased from 0.61% in the initial 5 years to 0.47% in the most recent 5 years, with statistical significance. Liver metastasis and type 2 biliary abnormality were significantly associated with the development of liver abscess. Mortality directly associated with liver abscess was 7.73% and was gradually decreasing, from over 50% in the 1990s to 5.48% in the past decade, with a statistically significant difference. Conclusions: The formation of liver abscess was a relatively low-incidence complication following TACE for malignant liver tumors, with clearly defined risk factors. Moreover, both the incidence and mortality rates of liver abscess were gradually decreasing. These findings provide valuable insights for future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.